Bicycle Therapeutics (BCYC) News Today $10.14 -0.33 (-3.15%) Closing price 04:00 PM EasternExtended Trading$10.30 +0.16 (+1.63%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Analysts Set Expectations for BCYC Q1 EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Bicycle Therapeutics in a report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($0.87March 4 at 5:46 AM | marketbeat.comPrincipal Financial Group Inc. Lowers Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Principal Financial Group Inc. decreased its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 406,470 shares of thMarch 4 at 3:06 AM | marketbeat.comAnalysts Set Bicycle Therapeutics plc (NASDAQ:BCYC) PT at $29.14March 4 at 1:23 AM | americanbankingnews.comBicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low - Should You Sell?Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low - Here's WhyMarch 3 at 12:40 PM | marketbeat.comHC Wainwright Issues Pessimistic Forecast for BCYC EarningsMarch 2 at 1:49 AM | americanbankingnews.comBrokers Offer Predictions for BCYC FY2025 EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Bicycle Therapeutics in a research note issued on Wednesday, February 26th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn (March 1 at 8:30 AM | marketbeat.comHC Wainwright Issues Negative Estimate for BCYC EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Analysts at HC Wainwright decreased their Q1 2025 earnings estimates for Bicycle Therapeutics in a research note issued on Wednesday, February 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per shMarch 1 at 7:35 AM | marketbeat.comQ1 EPS Estimate for Bicycle Therapeutics Reduced by AnalystBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Research analysts at Leerink Partnrs lowered their Q1 2025 earnings estimates for shares of Bicycle Therapeutics in a report released on Tuesday, February 25th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earniMarch 1 at 7:35 AM | marketbeat.comFY2025 EPS Estimates for BCYC Raised by Cantor FitzgeraldMarch 1 at 3:29 AM | americanbankingnews.comBicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to theMarch 1 at 2:23 AM | marketbeat.comLeerink Partnrs Brokers Lower Earnings Estimates for BCYCMarch 1 at 2:13 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Bicycle Therapeutics (NASDAQ:BCYC)March 1 at 1:27 AM | americanbankingnews.comFY2026 Earnings Estimate for BCYC Issued By Leerink PartnrsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Research analysts at Leerink Partnrs issued their FY2026 earnings estimates for Bicycle Therapeutics in a research report issued to clients and investors on Tuesday, February 25th. Leerink Partnrs analyst J. Chang anticipates that the companyFebruary 28, 2025 | marketbeat.comAnalysts Offer Predictions for BCYC FY2026 EarningsFebruary 28, 2025 | americanbankingnews.comRBC Capital Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)February 27, 2025 | markets.businessinsider.comBicycle Therapeutics (BCYC) Receives a Hold from Morgan StanleyFebruary 27, 2025 | markets.businessinsider.comBicycle Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagFebruary 26, 2025 | finance.yahoo.comBicycle Therapeutics price target lowered to $42 from $53 at JefferiesFebruary 26, 2025 | markets.businessinsider.comBarclays Remains a Buy on Bicycle Therapeutics (BCYC)February 26, 2025 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSBicycle Therapeutics (NASDAQ:BCYC - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company's revenue for the quarter was down 30.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.16) EPS.February 26, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $30.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday.February 26, 2025 | marketbeat.comBicycle Therapeutics' (BCYC) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday.February 26, 2025 | marketbeat.comBicycle Therapeutics reports Q4 EPS (75c), consensus (85c)February 25, 2025 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)February 25, 2025 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Hits New 12-Month Low - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Hits New 12-Month Low - What's Next?February 25, 2025 | marketbeat.comBicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 25, 2025 | finanznachrichten.deBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 25, 2025 | businesswire.comBicycle Therapeutics (BCYC): Among The Small–Cap Stocks Insiders Are Selling RecentlyFebruary 14, 2025 | msn.comBicycle Therapeutics (BCYC) Expected to Announce Quarterly Earnings on TuesdayBicycle Therapeutics (NASDAQ:BCYC) will be releasing earnings before the market opens on Tuesday, February 18, Financial Modeling Prep reports.February 11, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low - Time to Sell?Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 1-Year Low - Should You Sell?February 7, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) shareholders have endured a 74% loss from investing in the stock three years agoFebruary 5, 2025 | uk.finance.yahoo.comBicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | finance.yahoo.comBicycle Therapeutics plc (NASDAQ:BCYC) Given Average Rating of "Moderate Buy" by BrokeragesShares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have been given an average rating of "Moderate Buy" by the nine ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating toFebruary 4, 2025 | marketbeat.comBicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable DataFebruary 2, 2025 | seekingalpha.comBicycle Therapeutics plc (NASDAQ:BCYC) Sees Significant Growth in Short InterestBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 3,940,000 shares, an increase of 14.9% from the December 31st total of 3,430,000 shares. Based on an average daily volume of 591,800 shares, the days-to-cover ratio is presently 6.7 days.February 1, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Sees Large Volume Increase - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Sees Large Volume Increase - Here's What HappenedJanuary 31, 2025 | marketbeat.comBicycle Health reached profitability as it raised $16.5 million to scale virtual opioid use disorder treatment to more patients nationallyJanuary 30, 2025 | finance.yahoo.comResearch Analysts Issue Forecasts for BCYC FY2025 EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Bicycle Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($4.24) peJanuary 23, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Trading Down 5.2% - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Trading Down 5.2% - Here's WhyJanuary 22, 2025 | marketbeat.comBicycle Therapeutics' (BCYC) Equal Weight Rating Reaffirmed at StephensStephens reiterated an "equal weight" rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday.January 22, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Shares Down 3.9% - Time to Sell?Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 3.9% - Should You Sell?January 16, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Estimate for BCYC EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Investment analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for Bicycle Therapeutics in a research note issued on Monday, January 13th. Leerink Partnrs analyst J. Chang now anticipates that the company will postJanuary 16, 2025 | marketbeat.comOptimistic Outlook on Bicycle Therapeutics Amid Mixed Clinical Results and Strategic RoadmapJanuary 15, 2025 | markets.businessinsider.comBicycle Therapeutics: Promising Cancer Therapy Developments and Growth Opportunities Support Buy RatingJanuary 14, 2025 | markets.businessinsider.comForecasting The Future: 11 Analyst Projections For Bicycle TherapeuticsJanuary 14, 2025 | benzinga.comBicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and MilestonesJanuary 13, 2025 | stockhouse.comBicycle Therapeutics Announces Topline Phase 1 Data For Zelenectide Pevedotin Plus PembrolizumabJanuary 13, 2025 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Here's What HappenedJanuary 13, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $33.00 price target on shares of Bicycle Therapeutics in a research report on Monday.January 13, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Bicycle Therapeutics (NASDAQ:BCYC)Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday.January 13, 2025 | marketbeat.com Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Media Mentions By Week BCYC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCYC News Sentiment▼0.250.70▲Average Medical News Sentiment BCYC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCYC Articles This Week▼405▲BCYC Articles Average Week Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Viking Therapeutics News Today MorphoSys News Today HUTCHMED News Today Xenon Pharmaceuticals News Today Amneal Pharmaceuticals News Today Catalyst Pharmaceuticals News Today Bausch Health Companies News Today Recursion Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Vericel News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCYC) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts